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Results: From September 2011 to December 2013, 80 
patients were enrolled and two patients withdrew consent, 
finally 78 patients included for analysis. There were 73 male 
and 5 female. There were 96.2% of them had 0-1 WHO ECOG. 
For the primary site, 23(29.5%) patients were oral cavity, 26 
(33.3%) patients were oropharynx, 24(30.8%) patients were 
hypopharynx, and 5 (6.4%) patients were larynx. Treatment 
compliance was well. There were 92.3% patients completed 
planned schedule. After the induction chemotherapy, the 
overall response rate were 92.3%, which included 37.2% 
complete response and 55.1% partial response, respectively. 
Only 2(2.6%) patients had stable disease and 1(1.3%) patient 
had progression disease. The response rate of oral cavity, 
oropharynx, hypopharynx, and larynx were 82.6%, 92.3%, 
100%, 100%, respectively. There were 47.4% grade 3 or 4 
neutropenia and 20.5% grade 3 anemia. Only 6 severe adverse 
event were report, including 4 febrile neutropenia with 
sepsis, one osteomyelitis, and one massive bleeding. 
 
Conclusion: This outpatient docetaxel-based neoadjuvant 
chemotherapy regimen is a effective regimen in locally 
advanced squamous cell carcinoma of head and neck. 
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Purpose or Objective: The goal of this study is was to 
evaluate the results of treatment of T1N0M0 glottic cancer 
with irradiation, with emphasis on the influence of time from 
diagnosis to the beginning of radiation therapy. 
 
Material and Methods: We performed the retrospective 
analysis of the group of 539 patients with T1N0M0 glottic 
cancer, treated with radiation therapy in the Center of 
Oncology in Cracow between years 1977 and 2004. In 481 
cases (89%) the tumor was limited to single vocal cord and in 
the remaining 58 involved both of them. Anterior commisure 
involvement was observed in 173 (32%) of the patients. 
According to the radiotherapy technique and fractionation 
scheldule, we have divided patients into three separate 
groups: I - two oblique fields, TD 60 Gy/24 - 277 patients 
(51%); II - two opposite fields, TD 60 Gy/30 - 160 (31%); III - 
one lateral photon-electron beam, TD 60 Gy/30 - 102 (19%). 
The average time from laryngeal biopsy to the beginning of 
radiotherapy was 56 days (range: 3 -145 days). The overall 
survival (OS) and disease- free survival (DFS) were calculated 
using the Kaplan - Meier method. Log - rank test was used to 
calculate differences between each groups, and the 
independent prognostic factors were selected by the Cox 
multiparameter analysis. 
 
Results: The 5-year OS and 10-year OS were 84% and 69%, 5- 
and 10-year DFS were 90% and 88%, and the 5- and 10-year LC 
rates were 89% and 87%, respectively. One- dimensional 
analysis revealed following prognostic factors for LC and DFS: 
tobbaco smoking, radiotherapy technique, and the anterior 
commisure involvement. The 5- and 10-year LC rates in the 
group of patients smoking less than 20 cigarettes a day were 
90% and 87%, compared to 76% and 70%, respectively, in the 
group smoking more than 20 cigarettes a day (p=0,01). 
Considering the RT technique, the lowest 5- and 10-year LC 
rates were observed in the group treated with opposite 
beams (80% and 78%, respectively), and the highest when the 
oblique fields were used - 91% and 88%, respectively 
(p=0,002). The tumor involvement of the anterior commisure 
decreased 5-year LC by 15% (92 to 77%), and 10- year LC rate 
by 19% (89 to 70%, respectively, p=0,000). The waiting time 
for the beginning of RT longer than 30 days from the biopsy 
was statistically significant poor prognostic factor for DFS and 
LC. 5- and 10- year LC rates in the group of patients who 
started RT during the period of 30 days from the biopsy were 
92% and 90%, respectively, and in the group which started 
treatment after that time, these LC rates were 84% and 82%, 
respectively (p=0,01). Tumor interior commisure involvement 
was proven to be an independent prognostic factor affecting 
DFS and LC. 
 
Conclusion:  
1. Radiation therapy is efficient method of treatment the 
T1N0M0 glottic cancer 
2. Prolonged time of waiting for the beginning of RT 
decreases the LC and DFS rates 
3. The tumor involvement of anterior laryngeal commisure 
proved to be an independent adverse prognostic factor for LC 
and DFS 
 
EP-1108  
Chemoimmunotherapy with hyperfractionated 
radiotherapy in head and neck carcinoma. 
R. Carmona Vigo
1Hospital Dr. Negrín, Radiation Oncology, Las Palmas de Gran 
Canaria, Spain 
1, J.M. Blanco1, M. Lloret1, R. Cabrera1, P.C. 
Lara1 
 
Purpose or Objective: The aim of the present study is to 
analyze clinical outcomes and toxicity in patients with 
locoregionally advanced head and neck carcinoma treated 
with concurrent hyperfractionated radiotherapy with 
Cetuximab and Carboplatin. 
 
Material and Methods: Forty-one patients (8 cases ST.III and 
33 cases ST.IV) were prospectively included in this study from 
September 2009 to November 2014. Radiotherapy consisted 
in hyperfractionated radiotherapy: 1.15-1.20 Gy/fraction, 
BID, 5 days/week during 7 weeks. The average dose 
administered was 80.2 Gy (79.2-80.5). Carboplatin was 
administered 5 mg/m2 before each fraction of radiotherapy. 
Cetuximab was administered 400 mg/m2 one week before 
hyperfractionated radiotherapy and then 250 mg/m2 weekly 
while radiotherapy. Seven patients were not evaluable for 
response (in 3 patients, Capecitabine was added to the 
treatment; in 1 patient nodal metastases came from a 
papillary thyroid carcinoma; 3 patients were not evaluable 
for response because 2 patients died within 30 days after 
treatment and 1 patient has not enough follow-up to be 
evaluated for response). 
 
Results: All but 2 of the 34 evaluable patients showed 
objective response (19 complete responses). The local 
relapse-free survival, cause specific survival, and overall 
survival was 58.7%, 57%, 49% at 5 years, respectively. Severe 
(GradeII/III) acneiform rash resulted predictive of Clinical 
Response (p=0,005), Local relapse (p=0,008), distant 
metastases (p=0,012) and tumour related dead free survival 
(p<0,0001). Severe (Grade III) acute cutaneous and mucosal 
toxicity was present in almost 60% of the cases.  
 
Conclusion: This protocol induces a high rate of clinical 
responses and excellent survival figures in patients 
developing an strong immune response after combined radio-
chemoimmunotherapy.  
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